Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4208MR)

This product GTTS-WQ4208MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4208MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4145MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ15359MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ4701MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ8078MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ6702MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ11747MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ14078MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-421
GTTS-WQ6455MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW